BioVie Announces New Clinical and Biomarker Findings from Phase 2 ADDRESS-LC Trial of Bezisterim
BioVie Inc. presented new clinical and biomarker data from its Phase 2 ADDRESS-LC trial of bezisterim at the 4th Long COVID International Conference.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BioVie Inc. presented new clinical and biomarker data from its Phase 2 ADDRESS-LC trial of bezisterim at the 4th Long COVID International Conference.
BioVie Inc. announced new biomarker findings from its Phase 2 ADDRESS-LC trial of bezisterim, which were presented at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop.
BioVie Inc. announced it has been invited to deliver two oral presentations at the upcoming AD/PD 2027 International Conference on Alzheimer's & Parkinson's Diseases in Barcelona.
BioVie Inc. reported its third-quarter 2026 financial results, noting a wider quarterly loss driven by increased research and development expenses for its Long COVID program.
BioVie Inc. has entered into a securities purchase agreement to raise approximately $4.74 million through the sale of 2,962,500 shares of common stock at $1.60 per share.
BioVie Inc. has been invited to deliver a late-breaking oral presentation regarding its Bezisterim Long COVID data at the 4th Long COVID International Conference 2026.